Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 282

1.

[Comparison of UICC and AJCC 8th edition TNM classifications in uropathology].

Compérat E, Varinot J, Eymerit C, Paner GP, Hansel DE, Amin MB, Moroch J.

Ann Pathol. 2019 Jan 30. pii: S0242-6498(18)30189-5. doi: 10.1016/j.annpat.2018.12.005. [Epub ahead of print] French.

PMID:
30711335
2.

Atlas of Ex Vivo Prostate Tissue and Cancer Images Using Confocal Laser Endomicroscopy: A Project for Intraoperative Positive Surgical Margin Detection During Radical Prostatectomy.

Panarello D, Compérat E, Seyde O, Colau A, Terrone C, Guillonneau B.

Eur Urol Focus. 2019 Jan 23. pii: S2405-4569(19)30004-5. doi: 10.1016/j.euf.2019.01.004. [Epub ahead of print]

PMID:
30683530
3.

Handling and Reporting of Pelvic Lymphadenectomy Specimens in Prostate and Bladder Cancer: A Web-based Survey by the European Network of Uropathologists (ENUP).

Prendeville S, Berney DM, Bubendorf L, Compérat E, Egevad L, Hes O, Kristiansen G, Oxley J, van Leenders GJLH, Varma M, van der Kwast T.

Histopathology. 2019 Jan 3. doi: 10.1111/his.13818. [Epub ahead of print]

PMID:
30604878
4.

Datasets for the reporting of neoplasia of the testis: recommendations from the International Collaboration on Cancer Reporting.

Berney DM, Comperat E, Feldman DR, Hamilton RJ, Idrees MT, Samaratunga H, Tickoo SK, Yilmaz A, Srigley JR.

Histopathology. 2019 Jan;74(1):171-183. doi: 10.1111/his.13736. Review.

PMID:
30565308
5.

Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel.

Soukup V, Čapoun O, Cohen D, Hernández V, Burger M, Compérat E, Gontero P, Lam T, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Sylvester R, Yuan Y, Zigeuner R, Babjuk M.

Eur Urol Focus. 2018 Nov 20. pii: S2405-4569(18)30337-7. doi: 10.1016/j.euf.2018.11.005. [Epub ahead of print] Review.

PMID:
30470647
6.

Reactivity of CK7 across the spectrum of renal cell carcinomas with clear cells.

Gonzalez ML, Alaghehbandan R, Pivovarcikova K, Michalova K, Rogala J, Martinek P, Foix MP, Mundo EC, Comperat E, Ulamec M, Hora M, Michal M, Hes O.

Histopathology. 2018 Nov 16. doi: 10.1111/his.13791. [Epub ahead of print]

PMID:
30444288
7.

[French ccAFU guidelines - Update 2018-2020: Bladder cancer].

Rouprêt M, Neuzillet Y, Pignot G, Compérat E, Audenet F, Houédé N, Larré S, Masson-Lecomte A, Colin P, Brunelle S, Xylinas E, Roumiguié M, Méjean A.

Prog Urol. 2018 Nov;28(12S):S46-S78. doi: 10.1016/j.purol.2018.07.283. Epub 2018 Oct 23. Review. French.

PMID:
30366708
8.

[French ccAFU guidelines - Update 2018-2020: Upper tract urothelial carcinoma].

Rouprêt M, Xylinas E, Colin P, Houédé N, Compérat E, Audenet F, Larré S, Masson-Lecomte A, Pignot G, Brunelle S, Roumiguié M, Neuzillet Y, Méjean A.

Prog Urol. 2018 Nov;28(12S):S32-S45. doi: 10.1016/j.purol.2018.07.284. Epub 2018 Oct 11. Review. French.

PMID:
30318333
9.

Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results.

Neuzillet Y, Raynaud JP, Dreyfus JF, Radulescu C, Rouanne M, Schneider M, Krish S, Rouprêt M, Drouin SJ, Comperat E, Galiano M, Cathelineau X, Validire P, Molinié V, Fiet J, Giton F, Lebret T, Botto H.

Horm Cancer. 2019 Feb;10(1):36-44. doi: 10.1007/s12672-018-0351-8. Epub 2018 Oct 6.

PMID:
30293206
10.

"High-grade oncocytic renal tumor": morphologic, immunohistochemical, and molecular genetic study of 14 cases.

He H, Trpkov K, Martinek P, Isikci OT, Maggi-Galuzzi C, Alaghehbandan R, Gill AJ, Tretiakova M, Lopez JI, Williamson SR, Montiel DP, Sperga M, Comperat E, Brimo F, Yilmaz A, Pivovarcikova K, Michalova K, Slouka D, Prochazkova K, Hora M, Bonert M, Michal M, Hes O.

Virchows Arch. 2018 Dec;473(6):725-738. doi: 10.1007/s00428-018-2456-4. Epub 2018 Sep 19.

PMID:
30232607
11.

[Prognostic value of PD-1/PD-L1 expression in upper tract urothelial carcinoma].

Campedel L, Seisen T, Cussenot O, Comperat E, Varinot J, Rouprêt M, Cancel-Tassin G.

Prog Urol. 2018 Dec;28(16):900-905. doi: 10.1016/j.purol.2018.08.009. Epub 2018 Sep 13. Review. French.

PMID:
30219646
12.

SIU-ICUD on bladder cancer: pathology.

Compérat E, Babjuk M, Algaba F, Amin M, Brimo F, Grignon D, Hansel D, Hes O, Malavaud B, Reuter V, van der Kwast T.

World J Urol. 2019 Jan;37(1):41-50. doi: 10.1007/s00345-018-2466-5. Epub 2018 Sep 14.

PMID:
30218308
13.

[ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology].

Pignot G, Houédé N, Roumiguié M, Audenet F, Brunelle S, Colin P, Compérat E, Larré S, Masson-Lecomte A, Neuzillet Y, Xylinas E, Méjean A, Rouprêt M; les membres du CCAFU Vessie.

Prog Urol. 2018 Oct;28(12):567-574. doi: 10.1016/j.purol.2018.07.003. Epub 2018 Sep 8. Review. French.

PMID:
30205925
14.

Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease.

Kamoun A, Cancel-Tassin G, Fromont G, Elarouci N, Armenoult L, Ayadi M, Irani J, Leroy X, Villers A, Fournier G, Doucet L, Boyault S, Brureau L, Multigner L, Diedhiou A, Roupret M, Compérat E, Blanchet P, de Reyniès A, Cussenot O.

Ann Oncol. 2018 Aug 1;29(8):1814-1821. doi: 10.1093/annonc/mdy224.

15.

Letter to the editor: reply to Valeria Barresi "HOXB13 is not expressed in pleomorphic giant cell carcinoma of the bladder".

Varinot J, Compérat E.

Virchows Arch. 2018 Jun 22. doi: 10.1007/s00428-018-2395-0. [Epub ahead of print] No abstract available.

PMID:
29934658
16.

Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.

Zinnall U, Weyerer V, Compérat E, Camparo P, Gaisa NT, Knuechel-Clarke R, Perren A, Lugli A, Toma M, Baretton G, Kristiansen G, Wirtz RM, Cheng L, Wullich B, Stoehr R, Hartmann A, Bertz S.

Hum Pathol. 2018 Oct;80:55-64. doi: 10.1016/j.humpath.2018.05.022. Epub 2018 Jun 6.

PMID:
29885409
17.

Two-photon optical imaging, spectral and fluorescence lifetime analysis to discriminate urothelial carcinoma grades.

Pradère B, Poulon F, Compérat E, Lucas IT, Bazin D, Doizi S, Cussenot O, Traxer O, Abi Haidar D.

J Biophotonics. 2018 Nov;11(11):e201800065. doi: 10.1002/jbio.201800065. Epub 2018 Jul 16.

PMID:
29806125
18.

Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy.

Léon P, Cancel-Tassin G, Drouin S, Audouin M, Varinot J, Comperat E, Cathelineau X, Rozet F, Vaessens C, Stone S, Reid J, Sangale Z, Korman P, Rouprêt M, Fromond-Hankard G, Cussenot O.

World J Urol. 2018 Sep;36(9):1495-1500. doi: 10.1007/s00345-018-2290-y. Epub 2018 Apr 20.

PMID:
29679140
19.

Multiparametric MRI for Suspected Recurrent Prostate Cancer after HIFU:Is DCE still needed?

Lotte R, Lafourcade A, Mozer P, Conort P, Barret E, Comperat E, Ezziane M, de Guibert PJ, Tavolaro S, Belin L, Boudghene F, Lucidarme O, Renard-Penna R.

Eur Radiol. 2018 Sep;28(9):3760-3769. doi: 10.1007/s00330-018-5352-z. Epub 2018 Apr 9.

PMID:
29633004
20.

[The role of biomarkers in the diagnosis, prognosis and therapy of patients with immuno-oncological treatments of genito-urinary carcinomas].

Compérat E, Eymerit C, Moroch J, Varinot J.

Aktuelle Urol. 2018 Apr;49(2):171-177. doi: 10.1055/a-0573-7895. Epub 2018 Mar 27. German.

PMID:
29587322

Supplemental Content

Loading ...
Support Center